No stone left unturned: Challenges encountered during recruitment of women with advanced ovarian cancer for a phase I study

被引:5
作者
Albrecht, Tara A. [1 ]
Taylor, Ann Gill [1 ]
机构
[1] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA
关键词
Clinical trial research; Cancer; Recruitment; Research methodology; CLINICAL-TRIAL; MEDICINE USE; COMPLEMENTARY; ONCOLOGY; BARRIERS; MASSAGE; THERAPY;
D O I
10.1016/j.apnr.2013.05.003
中图分类号
R47 [护理学];
学科分类号
1011 ;
摘要
The recruitment and accrual of participants for cancer clinical trial research is often challenging. Chronic low accrual rates negatively influence the findings and generalizability that can be drawn from the available pool of research. There is a need for further evidence regarding both unsuccessful and successful approaches and useful strategies that investigators have used to counter common recruitment challenges. During recruitment for an intervention study examining the safety, efficacy, and feasibility of a potentially novel supportive therapy, a variety of steps were taken to avoid and subsequently overcome potential and real recruitment challenges the investigators faced. In this article the authors provide an overview of common recruitment challenges as well as the actual challenges encountered, procedures and strategies implemented to counter these challenges, while investigating the combined intervention of flaxseed oil, fasting, caffeine, and exercise in women with recurrent or multi-drug resistant stage HI or IV ovarian cancer. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:245 / 250
页数:6
相关论文
共 50 条
  • [31] Escalating doses of paclitaxel and epirubicin in combination with cisplatin in advanced ovarian epithelial carcinoma: a phase I-II study
    Gebbia, V
    Di Marco, P
    Borsellino, N
    Gebbia, N
    Valerio, MR
    Fallica, G
    Tirrito, ML
    Valenza, R
    Citarrella, P
    Panici, PB
    ANTI-CANCER DRUGS, 2003, 14 (05) : 359 - 364
  • [32] Loss of skeletal muscle density during neoadjuvant chemotherapy in older women with advanced stage ovarian cancer is associated with postoperative complications
    van der Zanden, Vera
    van Soolingen, Neeltje J.
    Viddeleer, Alain R.
    Trum, Johannes W.
    Amant, Frederic
    Mourits, Marian J. E.
    Portielje, Johanneke E. A.
    Baalbergen, Astrid
    Souwer, Esteban T. D.
    van Munster, Barbara C.
    EJSO, 2022, 48 (04): : 896 - 902
  • [33] Acceptability and Feasibility of Early Palliative Care Among Women with Advanced Epithelial Ovarian Cancer: A Randomized Controlled Pilot Study
    Cusimano, Maria C.
    Sajewycz, Katrina
    Harle, Ingrid
    Giroux, Janet
    Hanna, Tracie
    Willing, Stephanie
    Martin, Vickie
    Francis, Julie-Ann
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA, 2021, 43 (06) : 707 - 715
  • [34] Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study
    Copeland, Larry J.
    Brady, Mark F.
    Burger, Robert A.
    Rodgers, William H.
    Huang, Helen Q.
    Cella, David
    O'Malley, David M.
    Street, Daron G.
    Tewari, Krishnansu S.
    Bender, David P.
    Morris, Robert T.
    Lowery, William J.
    Miller, David S.
    Dewdney, Summer B.
    Spirtos, Nick M.
    Lele, Shashikant B.
    Guntupalli, Saketh
    Ueland, Frederick R.
    Glaser, Gretchen E.
    Mannel, Robert S.
    DiSaia, Philip J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (35) : 4119 - +
  • [35] A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HIVI30181A, in Patients with Advanced Solid Cancer
    Lee, Hyun Jung
    Heo, Dae-Seog
    Cho, Joo-Youn
    Han, Sae-Won
    Chang, Hye-Jung
    Yi, Hyeon-Gyu
    Kim, Tae-Eun
    Lee, Se-Hoon
    Oh, Do-Youn
    Im, Seock-Ah
    Jang, In-Jin
    Bang, Yung-Jue
    CANCER RESEARCH AND TREATMENT, 2014, 46 (03): : 234 - 242
  • [36] A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer
    Vujaskovic, Zeljko
    Kim, Dong W.
    Jones, Ellen
    Lan, Lan
    Mccall, Linda
    Dewhirst, Mark W.
    Craciunescu, Oana
    Stauffer, Paul
    Liotcheva, Vlayka
    Betof, Allison
    Blackwell, Kimberly
    INTERNATIONAL JOURNAL OF HYPERTHERMIA, 2010, 26 (05) : 514 - 521
  • [37] A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer
    Lolkema, Martijn P.
    Arkenau, Hendrik-Tobias
    Harrington, Kevin
    Roxburgh, Patricia
    Morrison, Rosemary
    Roulstone, Victoria
    Twigger, Katie
    Coffey, Matt
    Mettinger, Karl
    Gill, George
    Evans, T. R. Jeffry
    de Bono, Johann S.
    CLINICAL CANCER RESEARCH, 2011, 17 (03) : 581 - 588
  • [38] Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer
    Oh, Do-Youn
    Doi, Toshihiko
    Shirao, Kuniaki
    Lee, Keun-Wook
    Park, Sook Ryun
    Chen, Ying
    Yang, Liqiang
    Valota, Olga
    Bang, Yung-Jue
    CANCER RESEARCH AND TREATMENT, 2015, 47 (04): : 687 - 696
  • [39] Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study
    Kristeleit, Rebecca
    Moreno, Victor
    Boni, Valentina
    Guerra, Eva M.
    Kahatt, Carmen
    Romero, Ignacio
    Calvo, Emiliano
    Baste, Neus
    Lopez-Vilarino, Jose A.
    Siguero, Mariano
    Alfaro, Vicente
    Zeaiter, Ali
    Forster, Martin
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 (11) : 1428 - 1436
  • [40] Phase I Study of Sunitinib and Erlotinib in Advanced Nonsquamous Non-small Cell Lung Cancer
    O'Mahar, Shannon E.
    Campbell, Toby C.
    Tien Hoang
    Seo, Songwon
    Kim, KyungMann
    Larson, Martha M.
    Marcotte, Sarah M.
    LoConte, Noelle K.
    Traynor, Anne M.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (05) : 951 - 953